Evidence map›Paper›PMID 36581934›Full record

ArticleHealth and quality of life outcomes2022

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.

T M Ripping, E Rammant, J A Witjes, N K Aaronson, M van Hemelrijck, L M C van Hoogstraten, BlaZIB study group, L A Kiemeney, K K H Aben

Abstract read
In one paragraph

Article in Health and quality of life outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

T M RippingDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, PO Box 19079, 3501, DB, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0002-2913-3531
E RammantKing's College London, Faculty of Life Sciences & Medicine, Translational Oncology & Urology Research (TOUR), London, UK.ORCID https://orcid.org/0000-0001-6130-2502
J A WitjesDepartment of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.
N K AaronsonDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-2574-4850
M van HemelrijckKing's College London, Faculty of Life Sciences & Medicine, Translational Oncology & Urology Research (TOUR), London, UK.ORCID https://orcid.org/0000-0002-7317-0858
L M C van HoogstratenDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, PO Box 19079, 3501, DB, Utrecht, the Netherlands.
BlaZIB study group
L A KiemeneyDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-2368-1326
K K H AbenDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, PO Box 19079, 3501, DB, Utrecht, the Netherlands. k.aben@iknl.nl.ORCID https://orcid.org/0000-0002-0214-2147

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundQuality of Life (QoL) of bladder cancer patients has been largely neglected. This is partly due to the lack of well-validated QoL questionnaires. The aim of this study is to examine the structural validity, reliability (i.e., internal consistency and test-retest reliability), construct validity (i.e., divergent validity and known group validity) and responsiveness of the Dutch version of the European Organisation for Research and Treatment of Cancer QoL questionnaire for muscle invasive bladder cancer (EORTC-QLQ-BLM30).

methodsPatients with newly diagnosed muscle invasive bladder cancer (MIBC) participating in the population-based 'Blaaskankerzorg In Beeld' (BlaZIB) study who completed the EORTC-QLQ-BLM30 at baseline were included. BlaZIB is a Dutch nationwide population-based prospective cohort study collecting clinical data and QoL data of bladder cancer patients. QoL is assessed with a self-administered questionnaire at four points in time: 6 weeks (baseline), 6 months, 12 months and 24 months after diagnosis. Confirmatory factor analysis and multitrait scaling analysis were used to investigate and adapt the scale structure. Reliability, construct validity and responsiveness of the revised scales were evaluated.

resultsOf the 1542 patients invited to participate, 650 patients (42.2%) completed the QLQ-BLM30 at baseline. The questionnaire's scale structure was revised into seven scales and eight single items. Internal consistency and test-reliability were adequate for most scales (Cronbach's α ≥0.70 and intraclass correlation coefficient ≥ 0.70, respectively), with the exception of the revised urostomy problem scale and abdominal bloating and flatulence scale. The questionnaire exhibited little overlap with the EORTC-QLQ-C30: all correlations were < 0.40, except for the correlation between emotional function (QLQ-C30) and future worries (QLQ-BLM30). The questionnaire was able to distinguish between patient subgroups formed on the basis of physical function, but not - as hypothesized- based on stage. Changes in health due to treatment were captured by the questionnaire, indicating that the questionnaire is responsive to change.

conclusionsThis study shows that the adapted scale structure of the EORTC-QLQ-BLM30 generally exhibits good measurement properties in Dutch patients, but needs to be validated in other languages and settings.

trial registrationBlaZIB, NL8106, www.trialregister.nl.

Indexed as

Quality of LifeUrinary Bladder NeoplasmsHumansMusclesProspective StudiesPsychometricsReproducibility of ResultsSurveys and QuestionnairesBladder cancerEORTC questionnairePatient-reported outcomes measuresQuality of lifeValidation studies

Identifiers

PMID36581934
PMCPMC9798594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.